Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Cardiac Science Announces Q3 Results

Q3 Revenue of $34.5 Million

Cardiac Science Corporation logo. (PRNewsFoto/Cardiac Science Corporation) (PRNewsFoto/)

News provided by

Cardiac Science Corporation

Nov 09, 2010, 05:10 ET

Share this article

Share toX

Share this article

Share toX

BOTHELL, Wash., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, today announced its financial results for the third quarter of 2010.

The Company's third quarter revenue of $34.5 million consisted of $11.8 million in cardiac monitoring products revenue, $18.1 million in defibrillation products revenue and $4.5 million in service revenue.

Defibrillation products revenue was down 16% compared to the prior year third quarter, due principally to the absence of any Japanese AED revenue in the current quarter as a result of the previously announced termination of our Japanese distribution arrangement, compared to approximately $2.9 million in the third quarter of last year. As previously announced, the Company has signed an agreement with a new Japanese distributor, but does not expect meaningful AED sales in Japan until the second half of 2011.  

Third quarter 2010 cardiac monitoring products revenue was down 9% compared to the prior year third quarter, due primarily to market softness and a temporary delay in availability of newly released products near quarter end. The Company was not able to ship approximately $1.0 million in recently introduced cardiac monitoring products that were ordered for delivery during the quarter due to initial delays in availability of components in quantities sufficient to meet demand. The Company expects to ship the backordered products during the fourth quarter.

Service revenue for the third quarter of 2010 was up 6% compared to the same quarter last year.

Gross margin was 46.7% for the third quarter of 2010. Gross margin for the third quarter of the prior year was 0.2%, including the effect of a charge of $18.5 million for estimated costs relating to a corrective AED field action. Excluding this charge, Pro Forma Gross Margin in the third quarter of 2009 would have been 47.8%. The slight decline in gross margin in the third quarter of 2010 compared to pro forma gross margin in the third quarter of 2009 was primarily the result of a lower proportion of defibrillation products revenue in the current year, as AEDs generally yield higher gross margins than cardiac monitoring products and services.

Operating expenses for the quarter were $22.5 million, compared to $22.8 million for the third quarter of 2009. Operating expenses in the current quarter included approximately $0.8 million in costs relating to the Company's efforts to sell all or a portion of the Company, including costs relating to the recently announced agreement with Opto Circuits (India) Ltd.

The Company reported a net loss of $6.4 million, or $0.27 loss per share, in the third quarter of 2010. This compares to a net loss of $66.5 million, or $2.85 per share, in the third quarter of 2009. Our net loss for the third quarter of 2009 included an initial charge of $18.5 million related to our AED corrective and a charge of $44.0 million to increase the valuation allowance against the Company's deferred income tax assets. EBITDA for the third quarter of 2010 was negative $4.7 million and Adjusted EBITDA, which excludes stock-based compensation expense, was negative $4.1 million.

The Company reported net cash used in operations of $4.0 million for the third quarter of 2010, including $2.7 million used in activities relating to the Company's ongoing AED corrective actions. The Company had $6.7 million in cash and cash equivalents as of September 30, 2010.

Pending Acquisition by Opto Circuits (India) Ltd

On October 19, 2010 the Company announced that it had entered into an Agreement and Plan of Merger with Opto Circuits (India) Ltd. ("Opto Circuits"), pursuant to which Opto Circuits has agreed to acquire all of the outstanding shares of Cardiac Science common stock for $2.30 per share. The transaction, which has been unanimously approved by the boards of directors of both companies, will take the form of an all-cash tender offer by a wholly-owned subsidiary of Opto Circuits, followed by a second-step merger of that subsidiary with Cardiac Science, as a result of which any shares that have not been validly tendered into the offer will be converted into the right to receive cash equal to the offer price of $2.30 per share. The tender offer by Opto Circuits, which was commenced on November 1, 2010, is subject to customary conditions, including that shares representing at least sixty percent (60%) of Cardiac Science's outstanding shares of common stock are validly tendered into the offer. The companies are targeting a fourth quarter 2010 closing, assuming satisfaction of closing conditions and successful execution of the tender offer process. Upon completion of the merger, Cardiac Science will become a wholly-owned subsidiary of Opto Circuits.

Non-GAAP and Pro Forma Financial Information

This news release contains a discussion of EBITDA, Adjusted EBITDA and Pro Forma Gross Margin which are non-GAAP financial measures provided as a complement to results provided in accordance with U.S. generally accepted accounting principles ("GAAP"). We define the term "EBITDA" as earnings before net interest, income taxes, depreciation, and amortization. We define "Adjusted EBITDA" as EBITDA before stock-based compensation and, in the case of the third quarter of 2009, before corrective action costs associated with a corrective AED field action. "Pro Forma Gross Margin" for the third quarter of 2009 refers to Gross Profit before costs associated with corrective actions as a percentage of Total Revenues. These measures are not substitutes for measures determined in accordance with GAAP, and may not be comparable to the same measures as reported by other companies. EBITDA and Adjusted EBITDA are an integral part of the internal management reporting and planning process and are the primary measures used by management to evaluate the operating performance of the Company. The components of these measures include the key revenue and expense items for which operating managers are responsible and upon which their performance is evaluated. The Company also uses Adjusted EBITDA for planning purposes and in presentations to its board of directors. Pro Forma Gross Margin for the third quarter of 2009 is being presented because of the impact of the extraordinary charges related to the corrective actions on the Company's Gross Margin for the three month period ended September 30, 2009. Presentation of Gross Margin excluding this charge allows for a comparison of the Company's performance on a basis that management believes is more consistent from period to period. Reconciliations of EBITDA and Adjusted EBITDA to Net Loss and Pro Forma Gross Margin to Gross Margin, the most comparable GAAP measures, are contained in this press release.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For more information,

Company Contact:

Investor Contact:

Media Contact:

Mike Matysik

Cardiac Science Corporation

Senior Vice President and CFO

425.402.2009

Matt Clawson

Allen & Caron

949.474.4300

[email protected]

Christopher Gale

EVC Group Inc.

646.201.5431

203.570.4681

[email protected]


LOGO: http://www.cardiacscience.com/images/main_logo.gif

CSCX-F

– Tables to Follow –


Cardiac Science Corporation and Subsidiaries

Condensed Consolidated Statements of Operations (unaudited)

(in thousands, except share and per share amounts)














Three Months Ended September 30,





2010


2009





$

%


$

%

Revenues:







Cardiac monitoring products

$      11,836

34.3%


$      13,000

33.4%


Defibrillation products

18,149

52.6%


21,646

55.7%




Total product revenues

29,985

87.0%


34,646

89.1%


Service

4,495

13.0%


4,238

10.9%




Total revenues

34,480

100.0%


38,884

100.0%










Cost of revenues:







Products

15,244

50.8%


17,194

49.6%


Corrective action costs

-

n/m


18,500

47.6%


Service

3,149

70.1%


3,095

73.0%




Total cost of revenues

18,393

53.3%


38,789

99.8%










Gross profit:







Products

14,741

49.2%


17,452

50.4%


Service

1,346

29.9%


1,143

27.0%




Gross profit

16,087

46.7%


95

0.2%










Operating expenses:







Research and development

4,266

12.4%


4,270

11.0%


Sales and marketing

11,215

32.5%


11,923

30.7%


General and administrative

7,058

20.5%


6,571

16.9%




Total operating expenses

22,539

65.4%


22,764

58.5%













Operating loss

(6,452)

-18.7%


(22,669)

-58.3%










Other income:







Interest income

7

0.0%


23

0.1%


Other income, net

229

0.7%


158

0.4%












Total other income

236

0.7%


181

0.5%



















Loss before income tax expense:

(6,216)

-18.0%


(22,488)

-57.8%


Income tax expense

(117)

-0.3%


(43,923)

-113.0%










Net loss

(6,333)

-18.4%


(66,411)

-170.8%


Less:  Net income attributable to noncontrolling interests

(43)

-0.1%


(135)

-0.3%



















Net loss attributable to Cardiac Science Corporation

$      (6,376)

-18.5%


$    (66,546)

-171.1%










Net loss per share attributable to Cardiac Science Corporation:    







Basic

$        (0.27)



$        (2.85)



Diluted

$        (0.27)



$        (2.85)


Weighted average shares outstanding:







Basic

23,831,807



23,368,778



Diluted

23,831,807



23,368,778


Cardiac Science Corporation and Subsidiaries

Condensed Consolidated Statements of Operations (unaudited)

(in thousands, except share and per share amounts)














Nine Months Ended September 30,





2010


2009





$

%


$

%

Revenues:







Cardiac monitoring products

$      37,362

36.0%


$      40,151

35.0%


Defibrillation products

53,062

51.2%


61,413

53.6%




Total product revenues

90,424

87.2%


101,564

88.6%


Service

13,266

12.8%


13,098

11.4%




Total revenues

103,690

100.0%


114,662

100.0%










Cost of revenues:







Products

46,319

51.2%


49,261

48.5%


Corrective action costs

11,000

12.2%


18,500

16.1%


Service

9,499

71.6%


9,376

71.6%




Total cost of revenues

66,818

64.4%


77,137

67.3%










Gross profit:







Products

33,105

36.6%


52,303

51.5%


Service

3,767

28.4%


3,722

28.4%




Gross profit

36,872

35.6%


37,525

32.7%










Operating expenses:







Research and development

13,100

12.6%


11,358

9.9%


Sales and marketing

36,429

35.1%


34,392

30.0%


General and administrative

20,652

19.9%


18,536

16.2%




Total operating expenses

70,181

67.7%


64,286

56.1%













Operating loss

(33,309)

-32.1%


(26,761)

-23.3%










Other income:







Interest income

25

0.0%


55

0.0%


Other income, net

323

0.3%


555

0.5%












Total other income

348

0.3%


610

0.5%



















Loss before income tax expense:

(32,961)

-31.8%


(26,151)

-22.8%


Income tax expense

(308)

-0.3%


(42,563)

-37.1%










Net loss

(33,269)

-32.1%


(68,714)

-59.9%


Less:  Net income attributable to noncontrolling interests

(204)

-0.2%


(476)

-0.4%



















Net loss attributable to Cardiac Science Corporation

$    (33,473)

-32.3%


$    (69,190)

-60.3%










Net loss per share attributable to Cardiac Science Corporation:    







Basic

$        (1.41)



$        (2.98)



Diluted

$        (1.41)



$        (2.98)


Weighted average shares outstanding:







Basic

23,717,287



23,209,181



Diluted

23,717,287



23,209,181


Cardiac Science Corporation and Subsidiaries

Condensed Consolidated Balance Sheets (unaudited)

(in thousands)












September 30, 2010


December 31, 2009

ASSETS





Current assets:






Cash and cash equivalents

$                       6,690


$                    26,866



Accounts receivable, net

20,781


24,228



Inventories

23,902


23,581



Prepaid expenses and other current assets

2,775


3,702




Total current assets

54,148


78,377









Other assets

687


872


Machinery and equipment, net of accumulated depreciation

8,019


8,406


Deferred income taxes

31


31


Intangible assets, net of accumulated amortization

25,183


27,988


Investments in unconsolidated entities

308


386











Total assets

$                     88,376


$                  116,060








LIABILITIES AND EQUITY





Current liabilities:






Accounts payable

$                     10,568


$                    11,030



Accrued liabilities

13,323


12,216



Warranty liability

3,933


4,028



Deferred revenue

7,744


7,919



Corrective action liabilities

18,757


15,249




Total current liabilities

54,325


50,442









Deferred income taxes

5,389


5,389











Total liabilities

59,714


55,831









Equity:






Cardiac Science Corporation shareholders' equity

27,211


58,936



Noncontrolling interests

1,451


1,293




Total equity

28,662


60,229











Total liabilities and equity

$                     88,376


$                  116,060

Cardiac Science Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows (unaudited)

(in thousands)






Three Months Ended






September 30,






2010

2009

Operating Activities:




Net loss

$ (6,333)

$ (66,411)









Adjustments to reconcile net loss




   to net cash used in operating activities:





Stock-based compensation

577

674



Depreciation and amortization

1,516

1,595



Amortization of debt issuance costs

45

-



Deferred income taxes

-

43,996










Changes in operating assets and liabilities, net of businesses acquired:






Accounts receivable, net

3,237

(5,552)




Inventories

634

9




Prepaid expenses and other assets

553

509




Accounts payable

(1,976)

1,672




Accrued liabilities

593

(672)




Warranty liability

(48)

56




Corrective action liabilities

(2,695)

18,500




Deferred revenue

(55)

539





Net cash used in operating activities

(3,952)

(5,085)















Investing Activities:




Purchases of machinery and equipment

(289)

(1,034)


Proceeds from repayment of note

80

27


Purchase of intangible assets

-

(370)





Net cash used in investing activities

(209)

(1,377)















Financing Activities:




Proceeds from exercise of stock options and issuance of




  shares under employee stock purchase plan

73

161


Minimum tax withholding on restricted stock awards

(12)

(13)


Debt issuance costs

(181)

-





Net cash provided by (used in) financing activities

(120)

148









Effect of exchange rate changes on cash and cash equivalents

86

74








Net change in cash and cash equivalents

(4,195)

(6,240)

Cash and cash equivalents, beginning of period

10,885

37,868

Cash and cash equivalents, end of period

$  6,690

$  31,628

Cardiac Science Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows (unaudited)

(in thousands)






Nine Months Ended






September 30,






2010

2009

Operating Activities:




Net loss

$ (33,269)

$ (68,714)









Adjustments to reconcile net loss




   to net cash used in operating activities:





Stock-based compensation

1,797

1,887



Depreciation and amortization

4,724

4,662



Amortization of debt issuance costs

45

-



Deferred income taxes

-

42,231










Changes in operating assets and liabilities, net of businesses acquired:






Accounts receivable, net

3,219

3,165




Inventories

(363)

(1,321)




Prepaid expenses and other assets

1,213

545




Accounts payable

(250)

(785)




Accrued liabilities

1,172

(963)




Warranty liability

(63)

65




Corrective action liabilities

3,508

18,500




Deferred revenue

(175)

(131)





Net cash used in operating activities

(18,442)

(859)















Investing Activities:




Purchases of machinery and equipment

(1,634)

(2,688)


Proceeds from repayment of note

82

110


Purchase of intangible assets

-

(370)


Cash paid for acquisitions

-

(54)





Net cash used in investing activities

(1,552)

(3,002)















Financing Activities:




Proceeds from exercise of stock options and issuance of




  shares under employee stock purchase plan

225

897


Minimum tax withholding on restricted stock awards

(106)

(110)


Debt issuance costs

(181)

-





Net cash provided by (used in) financing activities

(62)

787









Effect of exchange rate changes on cash and cash equivalents

(120)

47








Net change in cash and cash equivalents

(20,176)

(3,027)

Cash and cash equivalents, beginning of period

26,866

34,655

Cash and cash equivalents, end of period

$    6,690

$  31,628

Cardiac Science Corporation and Subsidiaries

Reconciliation of GAAP Results to Non-GAAP Results (unaudited)

(in thousands)


Reconciliation of Net Loss Attributable to Cardiac Science Corporation to Adjusted EBITDA


Three Months Ended

Three Months Ended


September 30, 2010

September 30, 2009



% of revenue


% of revenue

Net loss attributable to Cardiac Science Corporation

$   (6,376)

-18.5%

$ (66,546)

-171.1%

Depreciation and amortization

1,561

4.5%

1,595

4.1%

Interest income

(7)

0.0%

(23)

-0.1%

Income tax expense

117

0.3%

43,923

113.0%

EBITDA

(4,705)

-13.6%

(21,051)

-54.1%






Stock-based compensation

577

1.7%

674

1.7%

Corrective action costs

-


18,500







Adjusted EBITDA

$   (4,128)

-12.0%

$   (1,877)

-4.8%







Reconciliation of Gross Margin to Pro Forma Gross Margin


Three Months Ended


September 30, 2009



% of revenue

Gross profit

$         95

0.2%

Corrective action costs

18,500

47.6%

Pro forma gross profit

$  18,595

47.8%




CSCX-F



(Logo:  http://photos.prnewswire.com/prnh/20080306/AQTH510LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

SOURCE Cardiac Science Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.